Back to Search
Start Over
Radioimmunoimaging of 125I-labeled anti-CD93 monoclonal antibodies in a xenograft model of non-small cell lung cancer.
- Source :
-
Oncology Letters . Dec2019, Vol. 18 Issue 6, p6413-6422. 10p. - Publication Year :
- 2019
-
Abstract
- Lung cancer, especially non-small cell lung cancer (NSCLC), is the most common malignant tumor associated with poor prognosis. Angiogenesis plays a vital role in NSCLC, and could be used in tumor staging and therapy evaluation. CD93 (C1q receptor) is reportedly a key regulator of tumor angiogenesis. In the present study, the efficacy and specificity of a 125I-labeled CD93-specific monoclonal antibody (125I-anti-CD93 mAb) in detecting NSCLC xenografts were analyzed, and the association between CD93 expression and 125I-anti-CD93 mAb uptake by tumors was evaluated. The targeting ability of 125I-anti-CD93 mAb enabled its rapid, continuous and highly specific accumulation in CD93-expressing tumors in vivo. These results revealed the potential applicability of 125I-anti-CD93 mAb for non-invasive imaging diagnosis of CD93-positive NSCLC. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 17921074
- Volume :
- 18
- Issue :
- 6
- Database :
- Academic Search Index
- Journal :
- Oncology Letters
- Publication Type :
- Academic Journal
- Accession number :
- 140295548
- Full Text :
- https://doi.org/10.3892/ol.2019.11036